Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

OTLC Relative to the S&P 500

OTLC Relative to the Sector

Seasonal Chart Analysis

Analysis of the Oncotelic Therapeutics, Inc. (OTCMKT:OTLC) seasonal charts above shows that a Buy Date of January 1 and a Sell Date of April 15 has resulted in a geometric average return of 0.77% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 100.77% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

To download OTLC seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: OTLC